NkartaNKTX
About: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Employees: 157
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
142% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 19
6% less funds holding
Funds holding: 119 [Q3] → 112 (-7) [Q4]
8.03% less ownership
Funds ownership: 96.12% [Q3] → 88.09% (-8.03%) [Q4]
21% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 29
50% less capital invested
Capital invested by funds: $307M [Q3] → $155M (-$152M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
99% less call options, than puts
Call options by funds: $68K | Put options by funds: $6.72M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stifel Stephen Willey 20% 1-year accuracy 4 / 20 met price target | 759%upside $14 | Buy Maintained | 27 Mar 2025 |
Needham Gil Blum 5% 1-year accuracy 8 / 162 met price target | 575%upside $11 | Buy Reiterated | 27 Mar 2025 |
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 27 / 160 met price target | 1,004%upside $18 | Buy Reiterated | 27 Mar 2025 |
Financial journalist opinion
Based on 7 articles about NKTX published over the past 30 days









